osimertinib,tepotinib
astrazeneca,merck
['osimertinib', 'nsclc', 'sclc', 'tepotinib']
up to 30% of pts with egfrmut nsclc progressing on osimertinib develop metamp ph2 insight trial studied tepotinib with osimertinib in this setting -an area of urgent unmet need. rr 54.5%.
gr 3 tox - 23.9% only led to discontinuation in 6.8% exciting data! #esmo2022 
Thoracic Medical Oncologist @BartsHospital, PhD in genomic medicine @Imperialcollege, Representative @ACPUK & @BTOGorg, @FMLM_UK clinical Fellow ‘18 #SE15